CTNM (Contineum Therapeutics) OCF Margin %: 0.00% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CTNM Contineum Therapeutics Inc CTNM
17 GF Score
Price $15.46
! 2 Warning Signs
View Full Analysis

What is Contineum Therapeutics OCF Margin %?

Contineum Therapeutics CTNM -1.37% 17 OCF Margin % is 0.00% as of Jun. 2026. GuruFocus rates CTNM with a GF Score™ of 17/100. The stock has 2 warning signs investors should review. Among 952 Biotechnology companies, Contineum Therapeutics ranks worse than 105041.91% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Contineum Therapeutics's Cash Flow from Operations for the three months ended in Jun. 2026 was $-11.50 Mil. Contineum Therapeutics's Revenue for the three months ended in Jun. 2026 was $0.00 Mil. Therefore, Contineum Therapeutics's OCF Margin % for the quarter that ended in Jun. 2026 was 0.00%.

As of today, Contineum Therapeutics's current OCF Yield % is -9.15%.

The historical rank and industry rank for Contineum Therapeutics's OCF Margin % or its related term are showing as below:


During the past 5 years, the highest OCF Margin % of Contineum Therapeutics was 38.70%. The lowest was 38.70%. And the median was 38.70%.

CTNM's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -65.71
* Ranked among companies with meaningful OCF Margin % only.

Contineum Therapeutics OCF Margin % Related Terms

Contineum Therapeutics OCF Margin % Historical Data

* Premium members only.

The historical data trend for Contineum Therapeutics's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Contineum Therapeutics OCF Margin % Chart

Contineum Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
OCF Margin %
0.00 0.00 38.70 0.00 0.00

Contineum Therapeutics Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
CTNM
17GF Score
Contineum Therapeutics Inc CTNM
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Contineum Therapeutics OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Contineum Therapeutics's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-55.312/0
= %

Contineum Therapeutics's OCF Margin for the quarter that ended in Jun. 2026 is calculated as

OCF Margin=Cash Flow from Operations (Q: Jun. 2026 )/Revenue (Q: Jun. 2026 )
=-11.501/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
Contineum Therapeutics (CTNM) has a OCF Margin % of 0.00% as of Jun. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Contineum Therapeutics and its competitors. Over the past decade, Contineum Therapeutics' OCF Margin % has ranged from 38.70 to 38.70. According to the industry distribution chart, Contineum Therapeutics ranks #999999 out of 952 companies in the Biotechnology industry.
Is Contineum Therapeutics' OCF Margin % too high?
Contineum Therapeutics' current OCF Margin % is 0.00%. Over the past 10 years, this metric has ranged from a low of 38.70 to a high of 38.70. Based on the distribution chart, Contineum Therapeutics ranks #999999 out of 952 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Contineum Therapeutics has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Contineum Therapeutics' OCF Margin % compare to FDMT and PRME?
According to the Biotechnology industry distribution chart, Contineum Therapeutics ranks #999999 out of 952 companies for OCF Margin %. This places Contineum Therapeutics in the lower half of its industry. Historically, Contineum Therapeutics' own OCF Margin % has ranged from 38.70 to 38.70 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Contineum Therapeutics and its competitors. Contineum Therapeutics's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Contineum Therapeutics stock overvalued right now?
Contineum Therapeutics (CTNM) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. Contineum Therapeutics' overall GF Score™ is 17/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Contineum Therapeutics (CTNM), the current OCF Margin % is 0.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Contineum Therapeutics Business Description

Address 3565 General Atomics Court, Suite 200, San Diego, CA, USA, 92121
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.
17GF Score

Get the complete analysis for CTNM

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$15.46
Price